SOD3 and pulmonary fibrosis: The use of an association product that combines mesenchymal stromal cells (MSCs) with SOD3 was recognized as a promising strategy to counteract fibrotic processes: MSCs have already been reported to be effective in the early stages [162], but detrimental in the late stages [163] of pulmonary fibrosis, while SOD3 overexpression in the lung was recognized as being protective against the development of fibrosis [164].